On 4 January 2019, China’s National People’s Congress (NPC) released draft amendments to the Chinese patent law for public comments (English translation available upon request), proposing, among other issues; higher damages for patent infringement, more options for rewarding inventors under an employee invention remuneration scheme, and patent term extensions for design patents and pharmaceutical patents.
On January 4, China’s National People’s Congress (NPC) released draft amendments to the Chinese Patent Law, proposing expanded and enhanced protections that may provide real benefits to companies that develop new drugs. A potentially important condition to one of the key proposed changes specific to new drugs is that it would be available only for
We’ve added a new topic to Hogan Lovells’ LimeGreen IP: focused on guiding you through the regulatory regime governing Supplementary Protection Certificates in Europe. SPCs have for many years proved a fertile area for dispute. This is due to a number of factors including: lack of clarity in the governing legislation; the evolution of new types of medicines leading to questions